Baker BROS. Advisors LP Purchases 125,000 Shares of Xencor, Inc. (NASDAQ:XNCR)

Baker BROS. Advisors LP lifted its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 22.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 670,431 shares of the biopharmaceutical company's stock after acquiring an additional 125,000 shares during the quarter. Baker BROS. Advisors LP owned approximately 0.96% of Xencor worth $13,482,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Linden Thomas Advisory Services LLC grew its position in Xencor by 1.6% during the second quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company's stock valued at $826,000 after buying an additional 699 shares during the period. SG Americas Securities LLC bought a new position in Xencor during the second quarter valued at about $154,000. Diversified Trust Co grew its position in Xencor by 7.8% during the second quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company's stock valued at $266,000 after buying an additional 1,017 shares during the period. Louisiana State Employees Retirement System grew its position in Xencor by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 900 shares during the period. Finally, Baillie Gifford & Co. grew its position in Xencor by 3.3% during the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company's stock valued at $445,000 after buying an additional 744 shares during the period.

Xencor Price Performance

XNCR traded up $1.38 on Monday, reaching $26.98. The company had a trading volume of 550,448 shares, compared to its average volume of 605,769. The business has a 50 day simple moving average of $21.93 and a 200 day simple moving average of $20.51. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -8.00 and a beta of 0.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 52-week low of $15.31 and a 52-week high of $27.20.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.98) by $0.27. The business had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Xencor's quarterly revenue was down 81.9% on a year-over-year basis. During the same period last year, the firm posted ($0.40) earnings per share. As a group, sell-side analysts anticipate that Xencor, Inc. will post -3.71 EPS for the current year.

Insider Activity at Xencor

In other news, CEO Bassil I. Dahiyat sold 49,278 shares of the firm's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $24.07, for a total value of $1,186,121.46. Following the transaction, the chief executive officer now owns 352,615 shares in the company, valued at approximately $8,487,443.05. This trade represents a 12.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the transaction, the vice president now owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 121,328 shares of company stock valued at $2,879,673 over the last three months. 5.23% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

XNCR has been the subject of a number of research reports. BMO Capital Markets reiterated an "outperform" rating and set a $34.00 target price (up previously from $32.00) on shares of Xencor in a research report on Friday, November 8th. Wedbush reiterated an "outperform" rating and set a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $20.00 to $30.00 in a research report on Monday. Finally, Royal Bank of Canada increased their target price on shares of Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a research report on Thursday, September 26th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $36.50.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.